Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NYSE | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 29, 22 | -1.33 | -0.08 Decreased by -19.53 K% |
| Apr 26, 22 | -0.48 | -0.09 Decreased by -4.81 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 24.00 K Decreased by -98.51% | -15.30 M Increased by +32.43% | Decreased by -63.76 K% Decreased by -4.44 K% |
| Dec 31, 22 | 2.25 M Increased by +93.28% | -13.25 M Increased by +37.47% | Decreased by -590.36% Increased by +67.65% |
| Sep 30, 22 | 2.25 M Increased by +93.28% | -13.25 M Increased by +32.15% | Decreased by -590.36% Increased by +64.90% |
| Jun 30, 22 | 1.30 M Decreased by -49.38% | -28.84 M Decreased by -98.84% | Decreased by -2.22 K% Decreased by -292.79% |
| Mar 31, 22 | 1.61 M Decreased by -37.14% | -22.65 M Decreased by -56.13% | Decreased by -1.40 K% Decreased by -148.38% |
| Dec 31, 21 | 1.16 M Decreased by -67.70% | -21.19 M Decreased by -281.60% | Decreased by -1.82 K% Decreased by -1.08 K% |
| Sep 30, 21 | 1.16 M Decreased by -67.70% | -19.53 M Decreased by -251.72% | Decreased by -1.68 K% Decreased by -988.77% |
| Jun 30, 21 | 2.57 M Decreased by -20.80% | -14.51 M Decreased by -433.76% | Decreased by -565.28% Decreased by -573.96% |
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.